Presence of Newcomers Forcing Changes in Blockbuster HIV Drug Market

The HIV drug market is both changing and growing, driven by fierce competition from the new drugs on the market as well as the prevalence of the illness worldwide, and a longer life expectancy of patients already being treated. Health data consultants Datamonitor places a sales value of $ 9.3 billion dollars in 2007 on the antiretroviral therapy in the seven major markets, with estimates of growth to $ 15.1 billion dollars by 2017.

09-24-2008 | 13:24 hs.

Author: Cate Kirby |

See full article

Páginas: [1] - [2]

A report published by Datamonitor gave a total sales value of $ 9.3 billion dollars for the HIV drug market worldwide in 2007 (a growth rate of 11.3 percent between 2004-2007), and an estimated increase to $ 15.1 billion dollars by 2017, pushed by the prevalence of HIV in emerging countries, plus a longer life expectancy of patients who would continue treatment.

But the health consultants´ report also pointed out the fierce competition and changes to be expected in all the different classes of these antiretroviral drugs, pushed by newcomers onto the market and the fazing out of others due to patent expiry.

The HIV market is dominated by just a few companies. California-based Gilead is the current market leader with a portfolio of four marketed products and an integrase inhibitor in late stage development. Nucleoside reverse transcriptase inhibitor (NRTI) fixed dose combination (FDC) Truvada remained the bestselling drug in 2007 – it had revenue for $ 996 million dollars in the first half of 2008 ($ 1.5 billion dollars in 2007).

Atripla, a joint venture between Gilead and Bristol-Myers Squibb, is a cross-class fixed-dose combination brand that had sales of $ 679 million dollars in the first half of 2008 ($ 920 million dollars in 2007). It became the new gold standard for newly diagnosed patients, and was the fourth best-selling HIV drug worldwide despite only being sold in the U.S.

The market leader for much of the history of antiretroviral therapy, U.K.´s GlaxoSmithKline (GSK), was the strongest player but many of its brands are relatively old and face patent expiration. Among its eight marketed products is FDC Epzicom (also called Kivexa) – a Truvada competitor – but several independent studies have highlighted that Epzicom is both less efficacious in certain patients and associated with an increased risk of myocardial infarction.

Epzicom had sales of $ 404 million dollars in the first half of this year, below GSK´s own Combivir, at $ 416 million in the same period.

Additionally, several late-stage R&D setbacks over the past two years have left the GSK without any HIV compounds in clinical development.

The competition within the Protease Inhibitor (PI) class has also intensified. Two trials, the CASTLE and ARTEMIS studies, changed the dynamics in this class.

Abbott´s Kaletra, the leader (sales of $ 708 million in the first half of 2008) is now challenged by Bristol-Myers Squibb´s Reyataz ($ 623 million dollars in the same period) and Johnson & Johnson´s (J&J) Prezista. Although Kaletra continues to lead in the EU and Japan in terms of sales, Reyataz has been the number one in the U.S. market for the last three years.

The Datamonitor report anticipates that by 2017, Reyataz and Prezista could become the leading PIs across the seven major markets, pushing Kaletra out from leading to third PI. Despite Reyataz´s success, Bristol-Myers Squibb´s overall franchise success is also at risk with Sustiva´s patent expiry in 2013 (sales for $ 555 million in first half 2008), because the company has no visible follow-up compounds in development to make up for the shortfall.

Datamonitor expects the EU to favor Reyataz as well, once it receives first line approval there, probably in 2009.

Between September 2007 and January 2008, three new HIV drugs were approved by the regulators: Pfizer´s Selzentry, Merck & Co´s Isentress and Tibotec´s Intelence.

Isentress (with sales of $ 124 million dollars in first half of 2008) and Intelence are already being widely used in highly active antiretroviral therapy (HAART) regimens for treatment of experienced patients, but Selzentry´s launch has been slow.

Intelence, a non-nucleoside reverse transcriptase inhibitor (NNRTI) is being used as early as second line therapy despite the lack of supporting data for this patient group. This off-label use risks the future franchise of Tibotec´s second NNRTI, TMC278, which is targeted specifically at the treatment-naïve population, to be launched around 2011.

See full article

Páginas: [1] - [2]

how can i get this AMBUSH

Published by: jones phiri | 09-28-2008 | 19:36

THE CURE for HIV/AIDS.......AMBUSH

THE IDEA that AMBUSH cures AIDS
is being proven by the more than 400 individuals who have taken a dose of 60 ml three times daily for 21 days. The result is that AMBUSH 'KILLS' the virus by causing the protein envelope to rupture and the viral particles are discarded by the white blood cells. AMBUSH is able to 'KILL' the virus that are 'hiding' in the lymph system by its 'natural radioactive' properties. This process allows the body to 'return to normal health' with a corresponding immunity to that or those strains of the virus.

What is AMBUSH ?
AMBUSH is a radioactive isotope of uranium that is found in the 'palm' plant of which there are more than 3000 species. When ingested, AMBUSH causes the body temperature in the trunk area to rise to about 102 degrees when the individual is sleeping. The preparation takes four hours per batch, which is then given to the individuals for consumption 60 ml three times daily for 21 days. AMBUSH is a herbal preparation in this form but it contains an active ingredient which is a 'NEW' crystalline substance, a drug from the 'palm plant' similarly to ASPIRIN originating from the willow tree bark

RESULTS:
After 21 days on AMBUSH, ALL the individuals experienced a decrease in viral load to undetectable, an increase in cd4, increase in RBC, an improvement in general health such as more color to the face, decrease in Buffalo hump, an increase in gluteal muscles, a decrease to having no joint pains whereby individuals can bend to touch their toes, and walk up steps are but a few examples. There is also a dramatic increase in their sexual appetite beginning after the first week of therapy

DISCUSSION:
In any plant concoction such as percolated 'tea', there are 30-40,000 compounds, whi ch would take the scientific community twenty years to isolate one particular ingredient if they knew what they were looking for. The LORD GOD has given me seven steps to isolate the active ingredient, which is soft and metallic in nature and has a carbon- uranium-sulfur-(classified)-phentolamine configuration or structure. This is similar to Federick Kekule and the discovery of the benzene ring where he dreamt the structure.

As an antiviral and 'natural radioactivity' producing agent, AMBUSH is also effective against leukemia, lupus and HPV. Here I am saying that I have 'GIVEN' AMBUSH in the same 'strength' and dosage to patients with leukemia, lupus and HPV. A 35 year old male with HIV found it difficult to impossible to urinate was put on 'green tea' and water while the doctors contemplated prostrate surgery. One of the doctors gave him my number , I sent him a supply of AMBUSH an d he has not been given any more ARV's, since taking AMBUSH 18 months ago, is in 'good' health and has expressed a willingness to be examined by HIV investigators like many others who have taken AMBUSH.

I have sent this 'IDEA' to most HIV research agencies, scientist of the field, universities, hospitals, clinics, politicians and news agencies to which it is REJECTED because the name of THE LORD GOD is mentioned. He has steered me scientifically through the processes such as which plant and how to produce the active ingredient. What are the odds of a Florida Pharmacist picking a plant would contain the CURE for HIV/AIDS ?
I have never charged any of the people for their supply of AMBUSH but a life saving has been spent on the project with NO renumeration from any sources because AMBUSH falls outside the walls of modern medicine and research.

PROPOSAL:

My proposal is that I PROVE that AMBUSH CURES HIV/AIDS by giving it to a number of END-STAGE or DRUG-RESISTANT people and the scientific community watches their recovery. This proposal addresses the problem in that I have already outlaid the results to be obtained.

This IDEA is unconventional in that the scientific community has rejected AMBUSH because I say it is GOD given. Secondly if I wrote it according to certain standards, then it might be peer reviewed. However, THE LORD GOD has also shown me that there are five enzyme systems associated with the virus, reverse transcriptase, protease, fusion and two more of which causes the virus to be AIRBOURNE. This means that without DIVINE intervention mankind and ALL warm- blooded mammals will be extinct in a number of years.

The PROOF of what I am saying is found in scientific papers wherein it is found that when the protease cuts the viral strands, it cuts it at DIFFERENT lengths EVERY time, to which it should always be a valine at the end but is a different amino acid every time. This is why it is IMPOSSIBLE to produce a VACCINE.

Since this is NOT a hypothesis but there are about 400 individuals who have taken AMBUSH, here lies a vast area in which to check, recheck and confirm that AMBUSH CURES AIDS. Let it be mentioned that during the HIV reproductive cycle, reverse transcriptase converts viral RNA into DNA compatible to human genetic materials. Thus the human DNA has been 'hijacked' and since each person has a DIFFERENT DNA, then the new viral copy is unique to that person which shows that each individual has a DIFFERENT STRAIN of the virus. Consider two HIV positive people swapping viral strains and increasing its complexity with multiple partners.
It can also be proposed that they be revisited as proof that the strain or strains that they had were 'killed' at the time of taking AMBUSH considering that a person can catch as many different strains as there are people who are infected by HIV.
I am also willing to work with the scientific community in identifying those individuals who took AMBUSH and wish to be identified with this process notwithstanding that some are stigmatized while others are jubilant,

Once AMBUSH is verified as being able to accomplish that which is aforementioned then the next stage might be the natural and artificial synthesis of the substance.

Finally, if this is accepted or not, believed or not, THE LORD GOD always wins and this is the heavenly truth to which AMBUSH was divinely given to mankind for the CURE of HIV/AIDS and it will be here forever. Apostle Shada Mishe.

vapalmer@bellsouth.net

Here is a video taped presentation that I gave at t he Martin Luther King library in Washington

http://www.youtube.com/watch?v=8V53D1w__Po
http://www.youtube.com/watch?v=vPwuwlVBOV0
http://www.youtube.com/watch?v=ZejptOwMTzQ
http://www.youtube.com/watch?v=CqcTgIAhrhc
http://www.youtube.com/watch?v=f7HPKcT_iwY
http://www.youtube.com/watch?v=W9iQfgiYAnw
http://www.youtube.com/watch?v=i3RzRS6tJDM

Published by: Apostle Shada Mishe | 09-25-2008 | 18:13

Publish comment: